Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 4/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22256661 | 0.89 | SLCO1B1 (0.44) | SLCO1B1ABCB11DGAT1USP30PDE3B | |
| SCHEMBL22256952 | 0.85 | SLCO1B1 (0.39) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22256943 | 0.84 | SLCO1B1 (0.51) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22256579 | 0.83 | SLCO1B1 (0.40) | SLCO1B1ABCB11DGAT1USP30PDE3B | |
| SCHEMBL22230718 | 0.82 | SLCO1B1 (0.50) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22256699 | 0.78 | SLCO1B1 (0.53) | SLCO1B1ABCB11DGAT1USP30HIF1A | |
| SCHEMBL19715922 | 0.77 | SLCO1B1 (0.60) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22230711 | 0.76 | SLCO1B1 (0.44) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22256960 | 0.75 | SLCO1B1 (0.43) | SLCO1B1ABCB11PDE3BPDE3A | |
| SCHEMBL22230661 | 0.75 | SLCO1B1 (0.50) | SLCO1B1ABCB11PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | SLCO1B1 3685/4885ABCB11 3552/4885DGAT1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.